Shanghai Haohai Biological Tech Co - Asset Resilience Ratio
Shanghai Haohai Biological Tech Co (688366) has an Asset Resilience Ratio of 1.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Shanghai Haohai Biological Tech Co for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Shanghai Haohai Biological Tech Co's Asset Resilience Ratio has changed over time. See Shanghai Haohai Biological Tech Co net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haohai Biological Tech Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Shanghai Haohai Biological Tech Co worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥107.18 Million | 1.51% |
| Total Liquid Assets | CN¥107.18 Million | 1.51% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Haohai Biological Tech Co maintains only 1.51% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haohai Biological Tech Co Industry Peers by Asset Resilience Ratio
Compare Shanghai Haohai Biological Tech Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Shanghai Haohai Biological Tech Co (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Haohai Biological Tech Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.23% | CN¥87.85 Million ≈ $12.85 Million |
CN¥7.12 Billion ≈ $1.04 Billion |
+1.07pp |
| 2023-12-31 | 0.17% | CN¥11.76 Million ≈ $1.72 Million |
CN¥7.11 Billion ≈ $1.04 Billion |
+0.07pp |
| 2022-12-31 | 0.10% | CN¥6.75 Million ≈ $987.58K |
CN¥6.89 Billion ≈ $1.01 Billion |
+0.01pp |
| 2021-12-31 | 0.09% | CN¥6.38 Million ≈ $933.01K |
CN¥6.95 Billion ≈ $1.02 Billion |
-0.15pp |
| 2020-12-31 | 0.24% | CN¥15.14 Million ≈ $2.22 Million |
CN¥6.30 Billion ≈ $921.70 Million |
-1.59pp |
| 2018-12-31 | 1.83% | CN¥81.28 Million ≈ $11.89 Million |
CN¥4.44 Billion ≈ $649.18 Million |
+0.69pp |
| 2013-12-31 | 1.14% | CN¥7.09 Million ≈ $1.04 Million |
CN¥621.18 Million ≈ $90.90 Million |
-0.42pp |
| 2012-12-31 | 1.56% | CN¥7.00 Million ≈ $1.02 Million |
CN¥448.04 Million ≈ $65.56 Million |
-- |
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more